Dinutuximab
- Generic Name
- Dinutuximab
- Brand Names
- Unituxin, Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1363687-32-4
- Unique Ingredient Identifier
- 7SQY4ZUD30
- Background
Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant region...
- Indication
Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen ...
- Associated Conditions
- High Risk Neuroblastoma
- Associated Therapies
- -
Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Target Recruit Count
- 40
- Registration Number
- NCT06669013
- Locations
- 🇷🇺
Kulyova Svetlana, St. Petersburg, Russian Federation
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 62
- Registration Number
- NCT06450041
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Quadruple Immunotherapy for Neuroblastoma
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hong Kong Children's Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05754684
- Locations
- 🇭🇰
Hong Kong Children's Hospital, Hong Kong, Hong Kong
Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Prof. Franca Fagioli
- Target Recruit Count
- 22
- Registration Number
- NCT05558280
- Locations
- 🇮🇹
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita, Turin, Italy
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 8
- Registration Number
- NCT05373901
- Locations
- 🇨🇳
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳The Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04751383
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DinutuximabProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Drug: IrinotecanDrug: IsotretinoinProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: SargramostimDrug: Temozolomide
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT04238819
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪UZ Gent, Gent, Oost-Vlaanderen, Belgium
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.